Biomarkers of PARP inhibitor sensitivity

被引：21
|
作者：
Turner, Nicholas C. [1 ,2 ]
Ashworth, Alan [1 ]
机构：
[1] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
[2] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2011年 / 127卷 / 01期
关键词：
POLY(ADP-RIBOSE) POLYMERASE; HOMOLOGOUS RECOMBINATION; BREAST-CANCER; MUTANT-CELLS; DNA-DAMAGE; MUTATIONS; REPAIR; EXPRESSION; SUPPRESSES; DEFICIENCY;
D O I：
10.1007/s10549-011-1375-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：283 / 286
页数：4
相关论文
共 50 条
  • [1] Biomarkers of PARP inhibitor sensitivity
    Nicholas C. Turner
    Alan Ashworth
    [J]. Breast Cancer Research and Treatment, 2011, 127 : 283 - 286
  • [2] Identification of gene expression biomarkers that predict sensitivity to the PARP inhibitor olaparib
    Lau, Alan
    Dry, Jonathan
    Harbron, Chris
    Knights, Charlotte
    Riches, Lucy
    Mangena, Ramu
    Avis, Tim
    Brown, Helen
    Runswick, Sarah
    Dearden, Simon
    O'Shaughnessy, Aisling
    Unwin, Louise
    Prime, John E.
    Hodgson, Darren
    Carmichael, James
    O'Connor, Mark J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [3] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
    Darren R. Hodgson
    Brian A. Dougherty
    Zhongwu Lai
    Anitra Fielding
    Lynda Grinsted
    Stuart Spencer
    Mark J. O’Connor
    Tony W. Ho
    Jane D. Robertson
    Jerry S. Lanchbury
    Kirsten M. Timms
    Alexander Gutin
    Maria Orr
    Helen Jones
    Blake Gilks
    Chris Womack
    Charlie Gourley
    Jonathan Ledermann
    J. Carl Barrett
    [J]. British Journal of Cancer, 2018, 119 : 1401 - 1409
  • [4] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
    Hodgson, D. R.
    Dougherty, B.
    Lai, Z.
    Grinsted, L.
    Spencer, S.
    O'Connor, M. J.
    Ho, T. W.
    Robertson, J. D.
    Lanchbury, J.
    Timms, K.
    Gutin, A.
    Orr, M.
    Jones, H.
    Gilks, B.
    Womack, C.
    Sun, J.
    Yelensky, R.
    Gourley, C.
    Ledermann, J.
    Barrett, J. C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S90 - S90
  • [5] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
    Hodgson, Darren R.
    Dougherty, Brian A.
    Lai, Zhongwu
    Fielding, Anitra
    Grinsted, Lynda
    Spencer, Stuart
    O'Connor, Mark J.
    Ho, Tony W.
    Robertson, Jane D.
    Lanchbury, Jerry S.
    Timms, Kirsten M.
    Gutin, Alexander
    Orr, Maria
    Jones, Helen
    Gilks, Blake
    Womack, Chris
    Gourley, Charlie
    Ledermann, Jonathan
    Barrett, J. Carl
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 1401 - 1409
  • [6] Mechanisms of PARP inhibitor sensitivity and resistance
    D'Andrea, Alan D.
    [J]. DNA REPAIR, 2018, 71 : 172 - 176
  • [7] Predicting PARP inhibitor sensitivity and resistance
    Bebb, D. Gwyn
    Lees-Miller, Susan P.
    [J]. CELL CYCLE, 2012, 11 (22) : 4110 - 4110
  • [8] Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
    Oplustilova, Lenka
    Wolanin, Kamila
    Mistrik, Martin
    Korinkova, Gabriela
    Simkova, Dana
    Bouchal, Jan
    Lenobel, Rene
    Bartkova, Jirina
    Lau, Alan
    O'Connor, Mark J.
    Lukas, Jiri
    Bartek, Jiri
    [J]. CELL CYCLE, 2012, 11 (20) : 3837 - 3850
  • [9] Sensitivity and resistance biomarkers to PARP inhibitors in Mcrpc.
    Mateo, Joaquin
    [J]. CANCER RESEARCH, 2018, 78 (16) : 21 - 22
  • [10] PREDICTORS OF SENSITIVITY TO COMBINED TEMOZOLOMIDE AND PARP INHIBITOR IN GLIOMA
    Nagashima, Hiroaki
    Higuchi, Fumi
    Lee, Christine
    Rafferty, Seamus
    Miller, Julie
    Wakimoto, Hiroaki
    Cahill, Daniel
    [J]. NEURO-ONCOLOGY, 2019, 21 : 72 - 72
12345